Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Hat Trick For Bluebird’s Beta-Thalassemia Gene Therapy

Executive Summary

bluebird bio is set to enter the EU market with the first gene therapy for transfusion-dependent β-thalassemia, after the European Medicines Agency reviewed its product in record time. Bluebird believes that the agency’s Priority Medicines (PRIME) and adaptive pathways programs have been instrumental in smoothing its path.

Advertisement

Related Content

New EU Market Hopefuls Await Their Fate; EMA Re-Adopting Zynteglo Opinion
European CHMP Opinions and MAA Updates
Bluebird Bio's Zynteglo Flies Through Its CHMP Review
Bluebird Bio's Zynteglo Flies Through Its CHMP Review
Bluebird’s Gene Therapy LentiGlobin Coming Into Land In The EU?
LentiGlobin Hogs The Limelight At CHMP’s First Amsterdam Meeting

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel